Prostate News Archive
11-Nov-2008
European Urology: Relationship Between Prostate Information And LUTS Evident (Medical News Today)
In the December issue of European Urology, Dr. Curtis Nickel and associates report on the evidence of a relationship between prostate inflammation and lower urinary tract symptoms (LUTS) in men enrolled in the REDUCE trial . Santaris Pharma releases positive data on LNA-based survivin inhibitor (News-Medical-Net)
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems. Circulating Tumor Cells Predict Survival Benefit From Treatment In Metastatic Castration-Resistant Prostate Cancer (Medical News Today)
UroToday.com - In the October 1, 2008 issue of Clinical Cancer Research, Dr. Johann de Bono and colleagues presented exciting data indicating that circulating tumor cells (CTC) predict overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). The Influence of Statin Medications on Prostate-Specific Antigen Levels (Marketwire via Yahoo! Finance)
www.UroToday.com - Christopher P. Evans, M.D. reports on the following: Dr. Robert J. Hamilton and associates report statin use lowers PSA levels, and as a result may confound the detection of prostate cancer in these patients.
Back to Prostate News Archive
